Despite encouraging clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant resistance from pharmacy benefit managers. The insurers are https://emiliedkna488819.free-blogz.com/89645198/the-vyndamax-faces-is-dealing-with-managed-care-organization-challenges-a-look-of-reimbursement-disputes